CD274 and gastric cancer: Findings from the CheckMate-649 study (55), the largest randomized phase III trial in gastric cancer by the European Society for Medical Oncology (ESMO), revealed that combining nivolumab with chemotherapy significantly prolonged overall survival in patients with a PD-L1 combined positive score (CPS) of ≥5, reducing the risk of death by 20% (HR 0.80, 95% CI 0.71-0.90, P = 0.0002).